150314-35-5

Docosatetraenoyl ethanolamide (DEA) is an endocannabinoid containing docosatetraenoic acid in place of the arachidonate moiety of AEA. DEA acts on CB₁ receptors with potency and efficacy similar to that of AEA. However, its specific role and relative importance as a cannabinergic neurotransmitter have not been elucidated.

(7Z,10Z,13Z,16Z)-N-(2-Hydroxyethyl)-7,10,13,16-docosatetraenamide is an endocannabinoid and an analog of anandamide, which is an endogenous cannabinoid and TRPV1 receptor agonist.

ChEBI: 7,10,13,16-Docosatetraenoylethanolamine is a N-acylethanolamine 22:4.

Potent endocannabinoid ( anandamide analog) that activates CB 1 receptors in microglia and binds to rat synaptosomal membranes (K I = 34.4 nM). Cannabimimetic in vivo .